Adalta (1AD.AX) Stock Price

Adalta Price

ASX·CLOSED
0.00
​
Market closed

Revenue has compounded at 7.4% per year over the past 14 years to 677,010.00 AUD. Adalta's net margin stands at -665.0%, down from -141.2% several years earlier.

Adalta stock price

Access this data via the Eulerpool API

Adalta business model & stock analysis

AdAlta Ltd. operates as a biotechnology company, discovers, develops, and commercializes protein based therapeutics. The firm is engaged in the development of therapeutic products from its i-body platform. The firm has five active development programs ranging from discovery to Phase II clinical trials with applications in the fields of inflammation/fibrosis and immuno-oncology. Its lead product, AD-214, is an antibody therapeutic for the treatment of fibrotic diseases, including lung fibrosis (specifically Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD)), kidney fibrosis, eye fibrosis and some cancers. Chimeric Antigen Receptor (CAR) cell therapies involve modification of a patient’s immune cells (T cells, NK cells, macrophages and other) so that they produce a CAR on the cell surface that enables the patient’s immune system to recognize and kill diseased cells such as cancer. The company develops i-body enabled PET (i-PET) imaging agents for use in immuno-oncology. The company evaluates several CXCR4 i-bodies.

Frequently asked questions about Adalta

7 analysts currently rate the Adalta stock: 0 recommend buying, 3 holding and 4 selling.

Converted at the current exchange rate, the Adalta share trades at 0.00 EUR (0.00 AUD).

The Adalta share (1AD.AX) is listed on 1 stock exchanges, including: ASX (1AD.AX).

The revenue cannot currently be calculated for Adalta.

The profit of Adalta is -4.68 M AUD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Adalta is currently -1.53. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Adalta stock.

The P/S cannot be calculated for Adalta currently.

The Eulerpool Quality Score for Adalta is 2/10.

The ISIN of Adalta is AU0000001AD2. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Adalta is 1AD.AX. The ticker symbol is used to trade Adalta shares on the stock exchange.

Fair ValueTerminal
0.00 AUD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Australia
Currency
AUD
Initial public offering
Aug 22, 2016
ISIN
AU0000001AD2
Cusip
Q0101X107
Market capitalization
2.72 M AUDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
7.35
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-1,265.31 %
Last updated Oct 8, 2026, 10:50 AM

Adalta Peer Group

Adalta Ticker

ASX · 1AD.AX

Adalta FIGI

1AD:AU · BBG00D9SX1C81AD:AT · BBG00D9SX1D71AD:AH · BBG00D9SX1J1

All fundamentals and in-depth analysis of Adalta

Our stock analysis for Adalta stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Adalta. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.